Insider Selling: Keryx Biopharmaceuticals (KERX) COO Sells 9,048 Shares of Stock

Keryx Biopharmaceuticals (NASDAQ:KERX) COO Christine A. Carberry sold 9,048 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $4.87, for a total value of $44,063.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at $4.86 on Monday. The stock has a market capitalization of $579.43, a price-to-earnings ratio of -3.24 and a beta of 4.93. Keryx Biopharmaceuticals has a 12-month low of $4.33 and a 12-month high of $8.38. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The company’s revenue was up 138.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.39) EPS. sell-side analysts forecast that Keryx Biopharmaceuticals will post -1.35 EPS for the current year.

Several equities research analysts have issued reports on KERX shares. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Stifel Nicolaus dropped their target price on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research report on Wednesday, November 8th. Finally, ValuEngine downgraded Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $7.44.

Several large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. increased its holdings in shares of Keryx Biopharmaceuticals by 1.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock worth $3,190,000 after purchasing an additional 4,388 shares during the period. Rhumbline Advisers increased its holdings in shares of Keryx Biopharmaceuticals by 0.3% in the second quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 335 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Keryx Biopharmaceuticals by 3.5% in the second quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock worth $6,963,000 after purchasing an additional 32,687 shares during the period. Legal & General Group Plc increased its holdings in shares of Keryx Biopharmaceuticals by 8.5% in the second quarter. Legal & General Group Plc now owns 28,205 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 2,220 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 590 shares during the period. Hedge funds and other institutional investors own 64.91% of the company’s stock.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/22/insider-selling-keryx-biopharmaceuticals-kerx-coo-sells-9048-shares-of-stock.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply